Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.
The rise of immunotherapy in cancer care has brought with it the challenge of managing adverse events (AEs). But immune-related AEs are known to be a sign that the treatment is working, and an pooled analysis of phase 3 trials involved atezolizumab (Tecentriq), presented during the 2021 American Society of Clinical Oncology Annual Meeting, show that the presence of low-grade AEs can, in fact, predict longer overall survival (OS).
Atezolizumab is currently approved in the first- and second-line settings for advanced non-small cell lung cancer (NSCLC). In an exploratory analysis, investigators pooled data from the IMpower 130, the IMpower 132, and the IMpower 150 studies, which evaluated the anti-PD-L1 agent in various combinations in treatment-naïve patients with nonsquamous stage IV NSCLC. The combinations were:
Analyses of immune-related AEs and survival took place at 1, 3, 6, and 12 months. In total, 2503 patients were included; 1577 in the atezolizumab arm and 926 in the control arm. Study protocols called for treatment interruption or discontinuation of AEs were grade 3 or higher.
Results showed:
The authors concluded that patients with grade 1 and 2 immune-related AEs had the longest OS and those with grade 3 or higher had the shortest, possibly due to discontinuation of therapy. They wrote that the data offer additional support for atezolizumab with chemotherapy in the first-line setting, with or without bevacizumab.
F. Hoffman-LaRoche funded the study.
Reference
Socinski MA, Jotte RM, Cappuzzo F, et al. Pooled analyses of immune-related adverse events (irAEs) and efficacy from thephase 3 trials IMpower130, IMpower132, and IMpower150. J Clin Oncol. 2021; 39(Suppl_15): abstr 9002. DOI: 10.1200/JCO.2021.39.15_suppl.9002
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
2 Commerce Drive
Cranbury, NJ 08512